We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Benign Hematology

Survey · September 24, 2019

Rivaroxaban or Apixaban for VTE With Elevated Bleeding Risk


Please complete the survey below. Your response will be tabulated and published anonymously to help inform other healthcare professionals.

For patients with VTE who have an elevated bleeding risk, which of the following describes your practice pattern?

Please sign in to complete this survey.

Additional Surveys

Further Reading